These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32933995)

  • 1. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
    Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
    Clin Cancer Res; 2020 Oct; 26(20):5487-5493. PubMed ID: 32933995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
    Hopkins AM; Kichenadasse G; McKinnon RA; Abuhelwa AY; Logan JM; Badaoui S; Karapetis CS; Rowland A; Sorich MJ
    Br J Cancer; 2022 Jan; 126(1):42-47. PubMed ID: 34711947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
    Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
    Eur Urol; 2020 Oct; 78(4):540-543. PubMed ID: 32660748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials.
    Hopkins AM; Badaoui S; Kichenadasse G; Karapetis CS; McKinnon RA; Rowland A; Sorich MJ
    J Thorac Oncol; 2022 Jun; 17(6):758-767. PubMed ID: 35183773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
    Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
    Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
    Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
    JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy.
    Li M; Zeng C; Yao J; Ge Y; An G
    Int Immunopharmacol; 2020 Nov; 88():106972. PubMed ID: 33182025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
    Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
    Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
    Fukuokaya W; Akazawa K; Kimura T
    Anticancer Res; 2024 May; 44(5):2117-2123. PubMed ID: 38677745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
    Baek YH; Kang EJ; Hong S; Park S; Kim JH; Shin JY
    Int J Cancer; 2022 Apr; 150(8):1291-1300. PubMed ID: 34877670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
    Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
    Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
    Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
    Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
    Front Immunol; 2021; 12():716317. PubMed ID: 34777340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
    Tomisaki I; Harada M; Minato A; Nagata Y; Kimuro R; Higashijima K; Harada K; Fujimoto N
    Anticancer Res; 2022 Mar; 42(3):1629-1634. PubMed ID: 35220261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis.
    Chang Y; Lin WY; Chang YC; Huang CH; Tzeng HE; Abdul-Lattif E; Wang TH; Tseng TH; Kang YN; Chi KY
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies.
    Sotelo M; Alonso-Gordoa T; Gajate P; Gallardo E; Morales-Barrera R; Pérez-Gracia JL; Puente J; Sánchez P; Castellano D; Durán I
    Clin Transl Oncol; 2021 Apr; 23(4):882-891. PubMed ID: 32897497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.